Volume 19, Number 4—April 2013
CME ACTIVITY - Research
Serotype IV and Invasive Group B Streptococcus Disease in Neonates, Minnesota, USA, 2000–20101
Patricia Ferrieri
, Ruth Lynfield, Roberta Creti, and Aurea E. Flores
, Ruth Lynfield, Roberta Creti, and Aurea E. Flores
Table 2
Serotype distribution of invasive GBS isolates for cultures collected from infants, Minnesota, USA, January 2000–December 2010*
| CPS type | No. (%) patients† |
||
|---|---|---|---|
| Early onset | Late onset | Total | |
| Ia | 79 (30.7) | 57 (29.7) | 136 (30.3) |
| Ib | 25 (9.7) | 12 (6.2) | 37 (8.2) |
| II | 43 (16.7) | 5 (2.6) | 48 (10.7) |
| III | 57 (22.2) | 95 (49.5) | 152 (33.9) |
| IV | 8 (3.1) | 4 (2.1) | 12 (2.7) |
| V | 39 (15.2) | 18 (9.4) | 57 (12.7) |
| VII | 2 (0.8) | 0 (0.0) | 2 (0.4) |
| Nontypeable |
4 (1.6) |
1 (0.5) |
5 (1.1) |
| Total | 257 (100.0) | 192 (100.0) | 449 (100.0) |
*GBS, group B Streptococcus; CPS, capsular polysaccharide serotype.
†Early-onset, patient age birth–6 days; late-onset, patient age 7–180 days.
1This work was presented in part at the XVIII Lancefield International Symposium on Streptococci and Streptococcal Diseases, September 4–8, 2011, Palermo, Italy.
Page created: March 14, 2013
Page updated: March 14, 2013
Page reviewed: March 14, 2013
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.